Buscar
Mostrando ítems 1-3 de 3
Artículo
Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial
(BMJ Publishing Group, 2015)
Introduction Finding therapeutic alternatives to carbapenems in infections caused by extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC) is imperative. Although fosfomycin was discovered more than 40 years ...
Artículo
Pharmacodynamics of fosfomycin: Insights into clinical use for antimicrobial resistance
(American Society for Microbiology, 2015-09-01)
The aim of this study was to improve the understanding of the pharmacokinetic-pharmacodynamic relationships of fosfomycin against extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli strains that have different ...
Artículo
Is reduced vancomycin susceptibility a factor associated with poor prognosis in MSSA bacteraemia?
(Oxford University Press, 2015)
Objectives: The known data about the influence of vancomycin MIC on Staphylococcus aureus bacteraemia are contradictory. Our objective was to study the possible impact of vancomycin MIC ≥1.5 mg/L on short- and medium-term ...